Through VEGF inhibition, pomalidomide exhibits antiangiogenic capacity and constitutes a promising therapeutic class that has been recently approved by the FDA for use in adult patients with HIV-related KS (after the failure of highly active antiretroviral therapy) and non-HIV-related KS [141]. This evidence concerns the gene VEGFA and Kaposi's sarcoma.